Loading…
← CockpitCompetitor Analysis › MPLT MapLight Therapeutics, Inc.Open in the cockpit ↗

MapLight Therapeutics, Inc.MPLTCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 6
Mkt cap
$370M
US dollars, full cap
Free float
22%
of shares outstanding
$/day
$2.62M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-149.0 pp
WACC 20.0%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$6.65
1D+1.2%
1W-11.1%
1M-19.3%
3M-40.8%
6M-76.1%
YTD-62.1%
1Y-51.4%
ATR %8.9%
Beta1.12
52w lowhigh83.5% off high

What MapLight Therapeutics does

Employees: 133

MapLight Therapeutics at a glance

Size MapLight Therapeutics (MPLT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $370M, the 2906th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.65 on 18 Nov 2026.

Performance Over six months the shares fell 76.1%, against -23.2% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 19 in its peer set.

Capital Return on invested capital runs 149.0 points below its cost of capital (20.0% WACC).

Short interest Short interest is 5.8% of the free float (30 Oct 2026).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 77MPLT 23
Six months, rebased to 100: MapLight Therapeutics against the median of its 20 peers (local-currency closes).

MapLight Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$584,000-$578,000-$701,000-$556,000-$574,000
EBITDA-$266M-$169M-$82.2M-$56.7M-$30.7M
Net income-$252M-$161M-$77.6M-$55.7M-$30.0M
Free cash flow-$179M-$139M-$79.6M-$52.5M-$27.3M
Capital expenditure$434,000$473,000$770,000$462,000$746,000
Total debt$1.69M$5.80M$6.58M$5.92M$6.27M

Quarterly statements and history in the cockpit →

MapLight Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-40%-20%0%002872SPRY301111PBYI688399005690301089UNICHEMLABIRD45524569000153002868488630053442CAVTXMPLT6-month return →1-month return →
Up and to the right = strong over both horizons. MapLight Therapeutics is the large dot.

MapLight Therapeutics competitors and peer comparison

How MapLight Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MapLight Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureMPLTPeer medianRank in peer set
1-month return-19.3%-13.3%4th lowest of 20
6-month return-76.1%-23.2%lowest of 19
Distance from 52-week high-83.5%-38.5%lowest of 21
ROIC minus cost of capital-149.0 pp-6.6 pp2nd lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%4.9×22.2%-15.7%
6467 6467.TWTaiwan$368Mn/an/a-2,618%1,407.9×n/an/a
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%7.2×n/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Pharmicell 005690.KSSouth Korea$364M-55%+46%32%3.0×-7.9%+24.8%
Tuoxin Pharmaceutical 301089.SZChina$363M-28%+17%-20%5.3×n/an/a
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%1.6×n/an/a
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%0.5×6.7%+4.2%
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%1.1×3.6%+3.1%
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
ASKA Pharmaceutical 4886.TJapan$354M-24%+11%n/an/an/an/a
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a

Questions

Which companies are MapLight Therapeutics's closest peers?
The cockpit's peer set: Tiansheng Pharmaceutical (002872.SZ), 6467 (6467.TW), ARS Pharmaceuticals (SPRY), Guangdong Lifestrong Pharmacy (301111.SZ), Puma Biotechnology (PBYI), Jiangsu Bioperfectus Technologies (688399.SS), Pharmicell (005690.KS), Tuoxin Pharmaceutical (301089.SZ).
How has MapLight Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -76.1% against -23.2% for the median peer; over one year -51.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.